硼替佐米减量BDT方案治疗老年多发性骨髓瘤疗效及安全性分析(3)
[4] Richardson P G， Sonneveld P， Schuster M， et al. Extended follow-up of phase 3 trial in relapsed multiple myeloma： final time-to-event results of the APEX trial[J]. Blood，2007，56(110)：3557-3560.[5] Harousseau J L， Attal M， Avet-Loiseau H， et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma： results ofthe IFM 2005-01 phase Ⅲ trial[J]. J Clin Oncol ......
您现在查看是摘要页，全文长 3274 字符。